SG11202005937QA - G1t38 superior dosage regimes - Google Patents
G1t38 superior dosage regimesInfo
- Publication number
- SG11202005937QA SG11202005937QA SG11202005937QA SG11202005937QA SG11202005937QA SG 11202005937Q A SG11202005937Q A SG 11202005937QA SG 11202005937Q A SG11202005937Q A SG 11202005937QA SG 11202005937Q A SG11202005937Q A SG 11202005937QA SG 11202005937Q A SG11202005937Q A SG 11202005937QA
- Authority
- SG
- Singapore
- Prior art keywords
- dosage regimes
- superior
- superior dosage
- regimes
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614952P | 2018-01-08 | 2018-01-08 | |
| US201862679575P | 2018-06-01 | 2018-06-01 | |
| US201962788017P | 2019-01-03 | 2019-01-03 | |
| PCT/US2019/012720 WO2019136451A1 (en) | 2018-01-08 | 2019-01-08 | G1t38 superior dosage regimes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005937QA true SG11202005937QA (en) | 2020-07-29 |
Family
ID=67143921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005937QA SG11202005937QA (en) | 2018-01-08 | 2019-01-08 | G1t38 superior dosage regimes |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11357779B2 (ru) |
| EP (1) | EP3738084A4 (ru) |
| JP (1) | JP2021509680A (ru) |
| KR (1) | KR20200108867A (ru) |
| CN (1) | CN111837146A (ru) |
| AU (1) | AU2019205821A1 (ru) |
| BR (1) | BR112020013915A2 (ru) |
| CA (1) | CA3087570A1 (ru) |
| CO (1) | CO2020008825A2 (ru) |
| IL (1) | IL275708A (ru) |
| MX (1) | MX2020007312A (ru) |
| PE (1) | PE20210121A1 (ru) |
| PH (1) | PH12020551050A1 (ru) |
| RU (1) | RU2020123665A (ru) |
| SG (1) | SG11202005937QA (ru) |
| WO (1) | WO2019136451A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2906166C (en) * | 2013-03-15 | 2023-03-14 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー１ セラピューティクス， インコーポレイテッド | 癌の治療に対する併用療法 |
| WO2019199883A1 (en) * | 2018-04-09 | 2019-10-17 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| CN115698014A (zh) | 2020-05-19 | 2023-02-03 | G1治疗公司 | 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物 |
| US20240000783A1 (en) * | 2020-08-13 | 2024-01-04 | Pfizer Inc. | Combination therapy |
| CA3212705A1 (en) * | 2021-03-17 | 2022-09-22 | Amgen Inc. | Sotorasib dosing regimen |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509580A (pt) | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| WO2006061712A2 (en) * | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| CN101945867A (zh) | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物 |
| ES2622559T3 (es) | 2008-07-29 | 2017-07-06 | Nerviano Medical Sciences S.R.L. | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico |
| JO2924B1 (en) | 2008-08-22 | 2015-09-15 | نوفارتيس ايه جي | Pyroloperimidine compounds and their uses |
| EP2341906A4 (en) | 2008-10-01 | 2012-06-13 | Univ North Carolina | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE INHIBITORS OF CYCLINE DEPENDENT KINASES 4/6 |
| EP2341911A4 (en) | 2008-10-01 | 2012-10-24 | Univ North Carolina | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6 |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| EP3025724B1 (en) | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| WO2011101277A1 (en) * | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Conjugated proteins |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| RU2621674C2 (ru) | 2010-10-25 | 2017-06-07 | Г1 Терапьютикс Инк., | Ингибиторы cdk |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| MX359406B (es) | 2011-07-01 | 2018-09-27 | Novartis Ag | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer. |
| JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| US8673972B2 (en) | 2012-08-03 | 2014-03-18 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| CA2906166C (en) | 2013-03-15 | 2023-03-14 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| JP6435315B2 (ja) * | 2013-03-15 | 2018-12-05 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 高活性抗新生物薬及び抗増殖剤 |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| US20160361314A1 (en) | 2013-08-28 | 2016-12-15 | Novartis Ag | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
| WO2015061407A1 (en) | 2013-10-24 | 2015-04-30 | Francis Xavier Tavares | Process for synthesis of lactams |
| US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| PL3091008T3 (pl) | 2013-12-31 | 2018-12-31 | Xuanzhu Pharma Co., Ltd. | Inhibitor kinazy i jego zastosowanie |
| WO2015161288A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| TW201618774A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040892A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies |
| EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| WO2017037576A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer |
| WO2017160568A1 (en) | 2016-03-16 | 2017-09-21 | Eli Lilly And Company | Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer |
| WO2017193141A1 (en) | 2016-05-06 | 2017-11-09 | Siyuan Zhang | Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer |
| SG11201811225RA (en) | 2016-06-22 | 2019-01-30 | Radius Health Inc | Ar+ breast cancer treatment methods |
| CN109803684B (zh) | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| WO2018091999A1 (en) | 2016-11-16 | 2018-05-24 | Pfizer Inc. | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| CN117530948A (zh) | 2016-12-05 | 2024-02-09 | G1治疗公司 | 化疗方案期间免疫反应的保持 |
| CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| EP4218820A3 (en) | 2017-03-16 | 2023-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| CN111148518A (zh) | 2017-03-30 | 2020-05-12 | 丹娜法伯癌症研究院 | 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法 |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| US20200113902A1 (en) | 2017-06-12 | 2020-04-16 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
| GB201709417D0 (en) | 2017-06-14 | 2017-07-26 | Inst Of Cancer Research: Royal Cancer Hospital | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer |
| TW201904574A (zh) | 2017-06-21 | 2019-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | ＳＥＲＤ與ＣＤＫ４／６抑制劑、ＰＩ３Ｋ／ｍＴＯＲ通路抑制劑的用途 |
| CA3066778A1 (en) | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN110913861B (zh) * | 2017-06-29 | 2024-01-09 | G1治疗公司 | G1t38的形态学形式及其制造方法 |
| CA3069561A1 (en) | 2017-08-03 | 2019-02-07 | Novartis Ag | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
| WO2019108589A1 (en) | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
-
2019
- 2019-01-08 WO PCT/US2019/012720 patent/WO2019136451A1/en unknown
- 2019-01-08 RU RU2020123665A patent/RU2020123665A/ru unknown
- 2019-01-08 KR KR1020207022923A patent/KR20200108867A/ko unknown
- 2019-01-08 JP JP2020537622A patent/JP2021509680A/ja active Pending
- 2019-01-08 SG SG11202005937QA patent/SG11202005937QA/en unknown
- 2019-01-08 CA CA3087570A patent/CA3087570A1/en active Pending
- 2019-01-08 MX MX2020007312A patent/MX2020007312A/es unknown
- 2019-01-08 PE PE2020000908A patent/PE20210121A1/es unknown
- 2019-01-08 CN CN201980017478.6A patent/CN111837146A/zh active Pending
- 2019-01-08 EP EP19736263.5A patent/EP3738084A4/en active Pending
- 2019-01-08 AU AU2019205821A patent/AU2019205821A1/en active Pending
- 2019-01-08 BR BR112020013915-7A patent/BR112020013915A2/pt unknown
-
2020
- 2020-06-28 IL IL275708A patent/IL275708A/en unknown
- 2020-07-08 PH PH12020551050A patent/PH12020551050A1/en unknown
- 2020-07-08 US US16/924,033 patent/US11357779B2/en active Active
- 2020-07-16 CO CONC2020/0008825A patent/CO2020008825A2/es unknown
-
2022
- 2022-06-13 US US17/839,215 patent/US20230149406A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3087570A1 (en) | 2019-07-11 |
| IL275708A (en) | 2020-08-31 |
| CN111837146A (zh) | 2020-10-27 |
| CO2020008825A2 (es) | 2020-07-31 |
| US20230149406A1 (en) | 2023-05-18 |
| US20200405721A1 (en) | 2020-12-31 |
| EP3738084A1 (en) | 2020-11-18 |
| AU2019205821A1 (en) | 2020-07-09 |
| EP3738084A4 (en) | 2021-11-17 |
| RU2020123665A (ru) | 2022-02-10 |
| JP2021509680A (ja) | 2021-04-01 |
| BR112020013915A2 (pt) | 2020-12-01 |
| KR20200108867A (ko) | 2020-09-21 |
| PH12020551050A1 (en) | 2021-08-23 |
| PE20210121A1 (es) | 2021-01-19 |
| MX2020007312A (es) | 2021-01-08 |
| WO2019136451A1 (en) | 2019-07-11 |
| US11357779B2 (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276232A (en) | pharmaceutical compounds | |
| GB2569961B (en) | Pharmaceutical | |
| GB2572126B (en) | Pharmaceutical | |
| GB2572125B (en) | Pharmaceutical | |
| IL275708A (en) | Preferred dosing regimens of G1T38 | |
| GB201713653D0 (en) | Dosage regimen | |
| GB201810245D0 (en) | Pharmaceutical compounds | |
| IL283900A (en) | Pharmaceutical combinations | |
| GB201818709D0 (en) | Mixer | |
| GB201810239D0 (en) | Pharmaceutical compounds | |
| GB201819961D0 (en) | Pharmaceutical compounds | |
| IL277334A (en) | Pharmaceutical combinations | |
| GB201819960D0 (en) | Pharmaceutical compounds | |
| IL279334A (en) | Pharmaceutical combinations | |
| GB201801562D0 (en) | Pharmaceutical compounds | |
| GB201800378D0 (en) | Pharmaceutical compounds | |
| IL269169A (en) | New dosage form | |
| GB201816369D0 (en) | Pharmaceutical compounds | |
| GB201607548D0 (en) | Solid dosage form | |
| GB201901989D0 (en) | Pharmaceutical combinations | |
| GB201808473D0 (en) | Dosage regime | |
| GB201808507D0 (en) | Dosage Regime | |
| GB201808101D0 (en) | Dosage regime | |
| GB201803298D0 (en) | Dosage regime | |
| GB201802679D0 (en) | Dosage regime |